Daniel Murphy

Steroid versus placebo injection for trigger finger

Daniel Murphy, Joseph M. Failla, Mark P. Koniuch · The Journal Of Hand Surgery · 1995 · 151 citations

Interventional Pain Medicine, Pain Medicine, Clinical Trials +7

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Protease Inhibitors, Treatment And Prevention, Pharmacology +9

Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort

Réjean Thomas, Chrissi Galanakis, Sylvie Vézina et al. · PLoS ONE · 2015 · 67 citations · Full text

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

Kathleen Squires, Benjamin Young, Edwin DeJesus et al. · AIDS · 2010 · 66 citations

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text